NASDAQ:VCNX Vaccinex 8/10/2026 Earnings Report $1.16 -0.13 (-10.08%) As of 12:02 PM Eastern Profile Vaccinex EPS ResultsActual EPSN/AConsensus EPS -$73.04Beat/MissN/AOne Year Ago EPSN/AVaccinex Revenue ResultsActual RevenueN/AExpected Revenue$0.05 millionBeat/MissN/AYoY Revenue GrowthN/AVaccinex Announcement DetailsQuarterDate8/10/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Vaccinex Earnings HeadlinesVaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026July 8, 2026 | globenewswire.comVaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025April 29, 2026 | quiverquant.comQYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.July 14 at 1:00 AM | Profits Run (Ad)Vaccinex Reports 2025 Annual Financial ResultsApril 29, 2026 | globenewswire.comVaccinex Inc.April 10, 2026 | barrons.comVaccinex announces $60M revenue sharing agreement with PDVDecember 23, 2025 | msn.comSee More Vaccinex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaccinex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaccinex and other key companies, straight to your email. Email Address About VaccinexVaccinex (NASDAQ:VCNX) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders. In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors. Concurrently, the company is conducting a pivotal Phase 2/3 study in early Huntington’s disease, evaluating pepinemab’s ability to slow cognitive and functional decline. Vaccinex’s pipeline also includes preclinical candidates targeting additional indications driven by SEMA4D biology, supported by collaborations with academic institutions and industry partners. Founded in the early 2000s, Vaccinex operates primarily in the United States, where it manages its clinical development, regulatory affairs and manufacturing activities. Under the leadership of President and CEO David Hallal, the company remains focused on advancing its strategic pipeline toward key regulatory milestones and potential commercialization, leveraging partnerships to broaden its research and development capabilities.View Vaccinex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Prepare for the Next Wave of Factory Automation With These 3 Standout NamesAnalysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software Costs Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
